COVID-19 vaccines: authorised
Vaccines authorised in the European Union (EU) to prevent COVID-19, following evaluation by the European Medicines Agency (EMA).
EMA is not involved in advising on travel requirements in the EU, such as vaccination, quarantine or testing for travellers.
Decisions about which COVID-19 vaccines are included, for example, in the EU Digital COVID Certificate, are taken by the EU Member States. EMA is in charge of the scientific evaluation of vaccines for EU marketing authorisation. The acceptability criteria for travel purposes are broader and can include, for example, World Health Organization (WHO) listed vaccines that have not necessarily undergone the EMA process of authorisation.
Official information on this topic is available in all EU languages at:
The table below lists the COVID-19 vaccines that can be used in the EU.
The marketing authorisation holders for these vaccines can apply for the authorisation of a version of their vaccine that has been adapted to address coronavirus variants.
EMA is evaluating these applications in an expedited manner, using its rolling review procedure.
Information on ongoing evaluations of adapted vaccines is available under 'Key milestones' in the table below.
|Vaccine||Marketing authorisation holder||Key milestones||More information|
|COVID-19 Vaccine (inactivated, adjuvanted) Valneva||Valneva Austria GmbH||Marketing authorisation issued: 24/06/2022|
|Nuvaxovid||Novavax CZ, a.s.|
Clinical data (login required)
|Vaxzevria (previously COVID-19 Vaccine AstraZeneca)||AstraZeneca AB|
Conditional marketing authorisation issued: 29/01/2021
Annual renewal issued: 09/11/2021
|Moderna Biotech Spain S.L.|
Annual renewal issued: 04/10/2021
Start of rolling review for adapted vaccine: 17/06/2022
Comirnaty (developed by BioNTech and Pfizer)
|BioNTech Manufacturing GmbH|
Conditional marketing authorisation issued: 21/12/2020
Annual renewal issued: 03/11/2021
Start of rolling review for adapted vaccine: 15/06/2022
|Janssen-Cilag International NV|
Conditional marketing authorisation issued: 11/03/2021
Annual renewal issued: 03/01/2022
For more information on how EMA evaluated these vaccines, see:
EMA monitors the safety of COVID-19 vaccines authorised in the EU extremely carefully. This enables the detection of any rare side effects that may emerge once many millions of people are vaccinated.
Safety updates on each COVID-19 vaccine are available:
EMA is actively involved in approving new manufacturing sites to increase manufacturing capacity and supply of COVID-19 vaccines in the EU:
- Increase in manufacturing capacity for Vaxzevria (previously COVID-19 Vaccine AstraZeneca)(24/01/2022)
- Increase in manufacturing capacity for COVID-19 vaccines from Janssen, Moderna and BioNTech/Pfizer (16/12/2021)
- Increase in manufacturing capacity for COVID-19 vaccine from AstraZeneca (01/12/2021)
- New manufacturing sites and new formulation approved for COVID-19 vaccine from BioNTech/Pfizer (18/10/2021)
- Additional manufacturing site for COVID-19 Vaccine Janssen (07/10/2021)